ArticleHaematologica2011
A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis.
Article in Haematologica, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 79 citations in OpenAlex.
- The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis.BMC nephrology · 2013Trial
- HFE-Related Hemochromatosis May Be a Primary Kupffer Cell Disease.Biomedicines · 2025Review
- Diagnosis and management of hereditary hemochromatosis: lifestyle modification, phlebotomy, and blood donation.Hematology. American Society of Hematology. Education Program · 2024Review
- Primary Non-HFE Hemochromatosis: A Review.Journal of clinical and translational hepatology · 2023Review
- Managing the Dual Nature of Iron to Preserve Health.International journal of molecular sciences · 2023Review
- Hepcidin and Iron in Health and Disease.Annual review of medicine · 2023Review
- The mutual crosstalk between iron and erythropoiesis.International journal of hematology · 2022Review
- Article
- Clinical Immunoassay for Human Hepcidin Predicts Iron Deficiency in First-Time Blood Donors.The journal of applied laboratory medicine · 2020Article
- Reduced iron export associated with hepcidin resistance can explain the iron overload spectrum in ferroportin disease.Liver international : official journal of the International Association for the Study of the Liver · 2020Article
- Hepcidin secretion was not directly proportional to intracellular iron-loading in recombinant-TfR1 HepG2 cells: short communication.Molecular and cellular biochemistry · 2020Article
- Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients.Pediatric nephrology (Berlin, Germany) · 2018Article
- Crossing the Iron Gate: Why and How Transferrin Receptors Mediate Viral Entry.Annual review of nutrition · 2018Review
- Whole-body iron transport and metabolism: Mechanistic, multi-scale model to improve treatment of anemia in chronic kidney disease.PLoS computational biology · 2018Article
- Low hepcidin in liver fibrosis and cirrhosis; a tale of progressive disorder and a case for a new biochemical marker.Molecular medicine (Cambridge, Mass.) · 2018Review
- HFE mRNA expression is responsive to intracellular and extracellular iron loading: short communication.Molecular biology reports · 2017Article
- Estimates of total body iron indicate 19 mg and 38 mg oral iron are equivalent for the mitigation of iron deficiency in individuals experiencing repeated phlebotomy.American journal of hematology · 2017Article
- Biomarkers of Functional Outcome in Intracerebral Hemorrhage: Interplay between Clinical Metrics, CD163, and Ferritin.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2017Article
- Detection of a rare mutation in the ferroportin gene through targeted next generation sequencing.Blood transfusion = Trasfusione del sangue · 2016Article
- Hepcidin in the diagnosis of iron disorders.Blood · 2016Review
Corrections and comments
- Commented on by
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundInadequate hepcidin production leads to iron overload in nearly all types of hemochromatosis. We explored the acute response of hepcidin to iron challenge in 25 patients with HFE-hemochromatosis, in two with TFR2-hemochromatosis and in 13 controls. Sixteen patients (10 C282Y/C282Y homozygotes, 6 C282Y/H63D compound heterozygotes) had increased iron stores, while nine (6 C282Y/C282Y homozygotes, 3 C282Y/H63D compound heterozygotes) were studied after phlebotomy-induced normalization of iron stores. DESIGN AND
methodsWe analyzed serum iron, transferrin saturation, and serum hepcidin by both enzyme-linked immunosorbent assay and mass-spectrometry at baseline, and 4, 8, 12 and 24 hours after a single 65-mg dose of oral iron.
resultsSerum iron and transferrin saturation significantly increased at 4 hours and returned to baseline values at 8-12 hours in all groups, except in the iron-normalized patients who showed the highest and longest increase of both parameters. The level of hepcidin increased significantly at 4 hours and returned to baseline at 24 hours in controls and in the C282Y/H63D compound heterozygotes at diagnosis. The hepcidin response was smaller in C282Y-homozygotes than in controls, barely detectable in the patients with iron-depleted HFE-hemochromatosis and absent in those with TFR2-hemochromatosis. Conclusions Our results are consistent with a scenario in which TFR2 plays a prominent and HFE a contributory role in the hepcidin response to a dose of oral iron. In iron-normalized patients with HFE hemochromatosis, both the low baseline hepcidin level and the weak response to iron contribute to hyperabsorption of iron.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.